| NCT Number | NCT04554914 |
| Lead Sponsor | Pierre Fabre Medicament |
| Conditions | Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant +3 more |
| Enrollment | 190 participants |
| Start Date | 2021-07-14 |
| Primary Completion | 2027-06 (estimated) |
| Study Completion | 2028-05 (estimated) |
| Updated on ClinicalTrials.gov | 2026-07-31 |